scholarly journals Parenteral Antiplatelet Agents in Three Patients Receiving VA-ECMO Support to Maintain Drug-Eluting Stent Patency

2021 ◽  
Vol 40 (4) ◽  
pp. S533
Author(s):  
B.M. Colvin ◽  
R. Rivosecchi
Keyword(s):  
Antiplatelet Agents ◽  
Ecmo Support ◽  
Drug Eluting Stent ◽  
Stent Patency ◽  
Drug Eluting ◽  
Va Ecmo

Short- and Midterm Adherence to Platelet P2Y12 Receptor Inhibitors After Percutaneous Coronary Intervention With Drug-Eluting Stents

2020 ◽  
Vol 25 (5) ◽  
pp. 466-471
Author(s):  
Fernando Morita ◽  
Mauricio Wajngarten ◽  
Marcelo Katz ◽  
Miguel Morita Fernandes-Silva ◽  
Adriano Caixeta ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Percutaneous Coronary Intervention ◽  
Antiplatelet Agents ◽  
Coronary Intervention ◽  
P2y12 Receptor ◽  
Drug Eluting Stent ◽  
P2y12 Inhibitors ◽  
Platelet Receptor ◽  
Percutaneous Coronary ◽  
Drug Eluting

Introduction/Objectives: In patients who have undergone recent percutaneous coronary intervention (PCI), poor adhesion to antiplatelet agents may increase the risk of stent thrombosis and death. We aimed to investigate the adherence to different P2Y12 receptor inhibitors after PCI with drug-eluting stent in stable and unstable patients and to evaluate the factors associated with low adherence. Method: In a prospective study conducted between 2014 and 2018, the 8-item Morisky scale was applied at 30 days and 6 months post-PCI to measure P2Y12 receptor inhibitors adherence. Also, we describe the characteristics of patients using different platelet receptor P2Y12 inhibitors. Regression models were used to identify predictors of poor adherence. Results: A total of 214 patients were included (65 ± 12 years, 81% man, 61% acute coronary syndromes). Patients in the clopidogrel group were older than those in the prasugrel (68 ± 12 vs 59 ± 11 years, P < .01, respectively) or ticagrelor group (68 ± 12 vs 62 ± 12 years, P < .01). Patients with low/moderate adherence at 30 days and 6 months represented, respectively, 19.8% and 27.5% of our sample. Current smokers and preexisting cardiovascular disease at presentation were associated with lower adherence at 30 days. Conclusions: We found substantial rates of moderate and low adherence to P2Y12 receptor inhibitors early after PCI. Current smokers and preexisting cardiovascular disease at presentation were associated with a lower likelihood of adherence. These results highlight the need of monitoring adherence to medical treatment after PCI.

Drug-eluting Stent Patency at 6 Months in the Pedal Artery of a Patient with Polyarteritis Nodosa: A Case Report

2013 ◽  
Vol 24 (6) ◽  
pp. 907-910 ◽  
Author(s):  
Massimo Venturini ◽  
Marcello Orsi ◽  
Michele Colombo ◽  
Giulia Querques ◽  
Giulia Agostini ◽  
...  
Keyword(s):  
Case Report ◽  
Polyarteritis Nodosa ◽  
Drug Eluting Stent ◽  
Stent Patency ◽  
Drug Eluting

scholarly journals Risk Factors for Coronary Drug-Eluting Stent Thrombosis: Influence of Procedural, Patient, Lesion, and Stent Related Factors and Dual Antiplatelet Therapy

2013 ◽  
Vol 2013 ◽  
pp. 1-8 ◽  
Author(s):  
Krishnankutty Sudhir ◽  
James B. Hermiller ◽  
Joanne M. Ferguson ◽  
Charles A. Simonton
Keyword(s):  
Risk Factors ◽  
Stent Thrombosis ◽  
Large Scale ◽  
First Generation ◽  
Randomized Clinical Trials ◽  
Antiplatelet Agents ◽  
Drug Eluting Stent ◽  
Related Factors ◽  
Vasomotor Function ◽  
Drug Eluting

The complication of stent thrombosis (ST) emerged at a rate of 0.5% annually for first-generation drug-eluting stents (DES), often presenting as death or myocardial infarction. Procedural factors such as stent underexpansion and malapposition are risk factors for ST in patients. The type of lesion being treated and lesion morphology also influence healing after treatment with DES and can contribute to ST. Second-generation DES such as the XIENCE V everolimus-eluting stent differ from the first-generation stents with respect to antiproliferative agents, coating technologies, and stent frame. Improvements in stent structure have resulted in a more complete endothelialization, thereby decreasing the incidence of ST. Bioresorbable scaffolds show promise for restoring vasomotor function and minimizing rates of very late ST. Post-PCI treatment with aspirin and clopidogrel for a year is currently the standard of care for DES, but high-risk patients may benefit from more potent antiplatelet agents. The optimal duration of DAPT for DES is currently unclear and will be addressed in large-scale randomized clinical trials.

scholarly journals Successful Prasugrel Therapy for Recurrent Left Main Stent Thrombosis in a Clopidogrel Hyporesponder

2015 ◽  
Vol 42 (5) ◽  
pp. 483-486 ◽  
Author(s):  
Yi-Sik Kim ◽  
Sang-Rok Lee
Keyword(s):  
Stent Thrombosis ◽  
Stent Implantation ◽  
Potential Role ◽  
Poor Response ◽  
Antiplatelet Agents ◽  
Drug Eluting Stent ◽  
Variable Response ◽  
Life Threatening ◽  
Drug Eluting

Stent thrombosis is a life-threatening sequela of drug-eluting stent implantation. Dual antiplatelet therapy with aspirin and thienopyridine is typically used to prevent this catastrophic event. In terms of stent thrombosis, the major concern is the variable response of patients to clopidogrel, and this has raised interest in new antiplatelet agents. We present the case of a 64-year-old woman whom we successfully treated with prasugrel after she had repeated episodes of stent thrombosis caused by a poor response to clopidogrel. This case highlights the potential role of new antiplatelet agents for patients who are undergoing drug-eluting stent implantation.

scholarly journals Optimal endpoint for drug-eluting stent: predictive value of minimum stent area for long-term stent patency

2002 ◽  
Vol 39 ◽  
pp. 71
Author(s):  
Yasuhiro Honda ◽  
Eberhard Grube ◽  
Toru Kataoka ◽  
Karl E. Hauptmann ◽  
Yoshihiro Morino ◽  
...  
Keyword(s):  
Predictive Value ◽  
Drug Eluting Stent ◽  
Stent Patency ◽  
Drug Eluting

scholarly journals Therapeutic Management of VA-ECMO Support for Cardiogenic Shock: Case Report.

2021 ◽  
Author(s):  
Hongfeng Yang ◽  
Jun Yan ◽  
Zhixin Yu ◽  
Yan Cai ◽  
Zhaochen Jin
Keyword(s):  
Extracorporeal Membrane Oxygenation ◽  
Cardiogenic Shock ◽  
Ecmo Support ◽  
Drug Eluting Stent ◽  
St Segment Elevation ◽  
Catheterization Laboratory ◽  
Cardiac Catheterization Laboratory ◽  
Membrane Oxygenation ◽  
Va Ecmo ◽  
Bridge Therapy

Abstract Introduction: Cardiogenic shock is considered a serious stage of heart disease, and there is no better way to treat this. Veno-arterial Extracorporeal membrane oxygenation (VA-ECMO) is a well-established technology that can be used as potential life-saving measures in patients who present with cardiac arrest or severe hemodynamic instability by improving organ perfusion and oxygenation. However, it is usually complex and needs individualized decisions in a multidisciplinary approach to manage patients receiving Extracorporeal membrane oxygenation, as defined clinical condition’s protocols are still lacking. Case presentation: one patient was a 44-year-old man with out-of-hospital ventricular fibrillation was transferred to our hospital after initial cardiopulmonary resuscitation. In the emergency department, he presented with ST-segment elevation extensive anterior wall myocardial infarction and cardiogenic shock with paroxysmal ventricular tachycardia. After transfer to intensive care unit, VA-ECMO was implanted due to worsening cardiogenic shock and recovered slowly thereafter. Another patient was a 58-year-old woman presented refractory hypotension. As a bridge-therapy, VA-ECMO support was implanted and then the patient was taken to the cardiac catheterization laboratory where she experienced Percutaneous coronary intervention and implanted a drug-eluting stent in the right coronary artery. Due to acute kidney injury, continuous renal replacement therapy was given to facilitate the control of fluid access balance, the removal of inflammatory media.Conclusion: VA-ECMO is not only used as a temporary treatment strategy for cardiogenic shock, but also as a bridge-therapy. It is important to focus on the improve the success rate of VA-ECMO treatment and avoid complications.

Sign in / Sign up

Export Citation Format

Share Document